Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
Mar 28, 2012, 04:30 ET
NEW YORK, March 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion", which provides insights into the anti-hypertensives therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of hypertension and pulmonary arterial hypertension. It also provides the share of generics in global anti-hypertensives and in each indication market. The report examines the global anti-hypertensives usage patterns. It includes the geographical distribution of hypertension and PAH disease markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the anti-hypertensives Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the anti-hypertensives market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the anti-hypertensives market.
GBI Research's analysis shows that the overall global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension, was valued at $29.9 billion in 2010. It grew from $19.1 billion in 2002 at a CAGR of 5.8%. The market is expected to witness a fluctuation due to patent expiries followed by generic erosion and the possible launch of novel molecules. The market is expected to witness comparatively slow growth with a CAGR of 1.2% between 2010 and 2017, to reach $32.6 billion in 2017. A steady increase in the hypertension and PAH prevalence population and the use of fixed dose combination drugs will drive the growth of the anti-hypertensives market in the future. The market for hypertension market is expected to slow down due to patent expiries of major blockbuster drugs. Recent and upcoming patent expiries of drugs are the only barrier to the global anti-hypertensives market. However, the expected launch of novel molecules with disease modifying characteristics and better safety and efficacy will drive the market in the forecast period.
Scope
- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension.
- Data and analysis on the anti-hypertensives market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain and Japan.
- Annualized market data for the anti-hypertensives market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in global anti-hypertensives market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Novartis, Daiichi Sankyo, Merck, Pfizer, AstraZeneca, Sanofi, Takeda and Boehringer Ingelheim.
- Key M&A activities and licensing agreements that took place between 2009 and 2011 in the anti-hypertensives market.
Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7
2 Global Anti-Hypertensives Market - Introduction 9
2.1 GBI Research Report Guidance 10
3 Global Anti-Hypertensives Market - Market Overview 11
3.1 Introduction 11
3.2 Revenue Forecasts for the Global Anti-Hypertensives Market 12
3.2.1 Revenue 12
3.2.2 Annual Cost of Therapy 13
3.2.3 Treatment Usage Patterns 14
3.3 Anti-Hypertensives Market Drivers 19
3.3.1 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and Pulmonary Arterial Hypertension 19
3.4 Anti-Hypertensives Market Restraints 19
3.4.1 Low Compliance in Hypertensive Patients 19
3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues 19
3.4.3 Low Treatment Seeking Behavior and Diagnosis in Pulmonary Arterial Hypertension 20
3.5 Generics Share in the Global Anti-Hypertensives Market 21
4 Global Anti-Hypertensives Market: Therapeutic Landscape 22
4.1 Hypertension 22
4.1.1 Introduction 22
4.1.2 Treatment Flow Algorithm for Hypertension 23
4.1.3 Revenue 23
4.1.4 Annual Cost of Therapy 25
4.1.5 Treatment Usage Patterns 27
4.1.6 Market Segmentation by Geography 32
4.2 Pulmonary Arterial Hypertension (PAH) Market 35
4.2.1 Introduction 35
4.2.2 Treatment Flow Algorithm for Pulmonary Arterial Hypertension 37
4.2.3 Revenue 38
4.2.4 Annual Cost of Therapy 39
4.2.5 Treatment Usage Patterns 40
4.2.6 Market Segmentation by Geography 45
5 Global Anti-Hypertensives Market - Geographical Landscape 48
5.1 Geographical Break-up 48
5.2 The US 51
5.2.1 Revenue 51
5.2.2 Annual Cost of Therapy 52
5.2.3 Treatment Usage Patterns 53
5.3 Top Five Countries in Europe 58
5.3.1 Revenue 58
5.3.2 Revenue by Country 59
5.3.3 Annual Cost of Therapy 60
5.3.4 Treatment Usage Patterns 62
5.4 Japan 67
5.4.1 Revenue 67
5.4.2 Annual Cost of Therapy 68
5.4.3 Treatment Usage Patterns 69
6 Global Anti-Hypertensives Market - Pipeline Analysis 74
6.1 Introduction 74
6.1.1 Research and Development Pipeline - Hypertension 76
6.1.2 Research and Development Pipeline - Pulmonary Arterial Hypertension 80
6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market 83
6.2.1 SPP635 83
6.2.2 Pioglitazone 83
6.2.3 LCZ696 84
6.2.4 QT1571 (Imatinib) 85
6.2.5 Selexipag (NS-304, ACT-293987) 86
6.2.6 PS-433540 (DARA) 86
6.2.7 Macitentan (ACT-064992, Actelion 1) 87
6.2.8 Riociguat (BAY63-2521) 88
7 Global Anti-Hypertensives Market - Competitive Landscape 90
7.1 Market Share Analysis 90
7.2 Competitive Profiling 91
7.2.1 Novartis 91
7.2.2 Merck 92
7.2.3 Daiichi Sankyo 93
7.2.4 Sanofi 94
7.2.5 AstraZeneca 95
7.2.6 United Therapeutics 97
7.2.7 Actelion 98
7.2.8 Pfizer 100
8 Global Anti-Hypertensives Market - Strategic Consolidations 102
8.1 Overview 102
8.2 Deals by Type 102
8.2.1 M&A Deals by Indication 103
8.2.2 M&A Deals by Year 103
8.2.3 M&A Deals by Geography 104
8.2.4 Summary of Major M&A Deals 105
8.3 R&D Licensing Agreements 107
8.3.1 Licensing Agreements by Indication 107
8.3.2 Licensing Agreements by Phase 108
8.3.3 Licensing Agreements by Geography 108
8.3.4 Licensing Agreements for Drugs in Phase II and Phase III Stage 109
8.3.5 Licensing Agreements for Approved Drugs 110
9 Global Anti-Hypertensives Market - Appendix 112
9.1 Market Definitions 112
9.2 Abbreviations 112
9.3 Research Methodology 114
9.3.1 Coverage 114
9.3.2 Secondary Research 114
9.3.3 Primary Research 114
9.3.4 Therapeutic Landscape 115
9.3.5 Market Size by Geography 116
9.3.6 Geographical Landscape 118
9.3.7 Pipeline Analysis 118
9.3.8 Competitive Landscape 118
9.3.9 Expert Panel Validation 118
9.4 Contact Us 118
9.5 Disclaimer 118
9.6 Sources 119
1.1 List of Tables
Table 1: Anti-Hypertensives Market, Global, Revenue ($bn), 2002-2010 12
Table 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2010-2017 12
Table 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002–2010 13
Table 4: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2010–2017 13
Table 5: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002–2010 14
Table 6: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2010–2017 15
Table 7: Hypertension Therapeutics Market, Global, Revenue ($bn), 2002–2010 24
Table 8: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 24
Table 9: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 26
Table 10: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 26
Table 11: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 27
Table 12: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 28
Table 13: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2010 33
Table 14: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2010–2017 34
Table 15: PAH Therapeutics Market, Global, Revenue ($m), 2002–2010 38
Table 16: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 38
Table 17: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 39
Table 18: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 39
Table 19: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002–2010 40
Table 20: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2010–2017 41
Table 21: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2002–2010 46
Table 22: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2010–2017 47
Table 23: Anti-Hypertensives Market, Global, Revenue by Geography ($bn), 2002–2010 49
Table 24: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2010–2017 50
Table 25: Anti-Hypertensives Market, The US, Revenue ($bn), 2002–2010 51
Table 26: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2010–2017 51
Table 27: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002–2010 52
Table 28: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2010–2017 52
Table 29: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002–2010 53
Table 30: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2010–2017 54
Table 31: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue ($bn), 2002–2010 58
Table 32: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010–2017 59
Table 33: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue by Country ($bn), 2002–2010 59
Table 34: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country ($bn), 2010–2017 60
Table 35: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2010 61
Table 36: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010–2017 61
Table 37: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2010 62
Table 38: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2010–2017 63
Table 39: Anti-Hypertensives Market, Japan, Revenue ($bn), 2002–2010 67
Table 40: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2010–2017 67
Table 41: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002–2010 68
Table 42: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2010–2017 68
Table 43: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002–2010 69
Table 44: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2010–2017 70
Table 45: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market, July 2011 77
Table 46: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market, 2011 81
Table 47: Anti-Hypertensives Market, Global, Major M&A Deals, 2005–2011 105
Table 48: Anti-Hypertensives Market, Global, Licensing Agreements for Drugs in Phase II and Phase III Stage, 2005–2011 109
Table 49: Anti-Hypertensives Market, Global, Licensing Agreements for Approved Drugs, 2005–2011 110
1.2 List of Figures
Figure 1: Anti-Hypertensives Market, Global, Drivers and Restraints, 2011 11
Figure 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2002–2017 12
Figure 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002–2017 13
Figure 4: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002–2017 14
Figure 5: Anti-Hypertensives Market, Global, Diseased Population (millions), 2002–2017 15
Figure 6: Anti-Hypertensives Market, Global, Treatment-Seeking Population (millions), 2002–2017 16
Figure 7: Anti-Hypertensives Market, Global, Diagnosed Population (millions), 2002–2017 17
Figure 8: Anti-Hypertensives Market, Global, Prescription Population (millions), 2002–2017 18
Figure 9: Anti-Hypertensives Market, Global, Branded versus Generic Market Share (%), 2010 21
Figure 10: Anti-Hypertensives Market, Treatment Flow Algorithm for Hypertension, 2011 23
Figure 11: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 24
Figure 12: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 25
Figure 13: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 27
Figure 14: Hypertension Therapeutics Market, Global, Diseased Population (millions), 2002–2017 28
Figure 15: Hypertension Therapeutics Market, Global, Treatment-Seeking Population (millions), 2002–2017 29
Figure 16: Hypertension Therapeutics Market, Global, Diagnosis Population (millions), 2002–2017 30
Figure 17: Hypertension Therapeutics Market, Global, Prescription Population (millions), 2002–2017 31
Figure 18: Hypertension Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017 32
Figure 19: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2017 33
Figure 20: PAH Therapeutics Market, Treatment Flow Algorithm for PAH, 2011 37
Figure 21: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2002–2017 38
Figure 22: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2017 39
Figure 23: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002–2017 40
Figure 24: PAH Therapeutics Market, Global, Diseased Population (thousand), 2002–2017 41
Figure 25: PAH Therapeutics Market, Global, Treatment-Seeking Population (thousand), 2002–2017 42
Figure 26: PAH Therapeutics Market, Global, Diagnosed Population (thousand), 2002–2017 43
Figure 27: PAH Therapeutics Market, Global, Prescription Population (thousand), 2002–2017 44
Figure 28: PAH Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017 45
Figure 29: PAH Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002–2017 46
Figure 30: Anti-Hypertensives Market, Global, Market Share by Geography (%), 2010 and 2017 48
Figure 31: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2002–2017 49
Figure 32: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2002–2017 51
Figure 33: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002–2017 52
Figure 34: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002–2017 53
Figure 35: Anti-Hypertensives Market, The US, Diseased Population (millions), 2002–2017 54
Figure 36: Anti-Hypertensives Market, The US, Treatment-Seeking Population (millions), 2002–2017 55
Figure 37: Anti-Hypertensives Market, The US, Diagnosed Population (millions), 2002–2017 56
Figure 38: Anti-Hypertensives Market, The US, Prescription Population (millions), 2002–2017 57
Figure 39: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002–2017 58
Figure 40: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country, ($bn), 2002-2017 59
Figure 41: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2017 61
Figure 42: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002–2017 62
Figure 43: Anti-Hypertensives Market, Top Five Countries in Europe, Diseased Population (millions), 2002–2017 63
Figure 44: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment-Seeking Population (millions), 2002–2017 64
Figure 45: Anti-Hypertensives Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002–2017 65
Figure 46: Anti-Hypertensives Market, Top Five Countries in Europe, Prescription Population (millions), 2002–2017 66
Figure 47: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2002–2017 67
Figure 48: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002–2017 68
Figure 49: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002–2017 69
Figure 50: Anti-Hypertensives Market, Japan, Diseased Population (millions), 2002–2017 70
Figure 51: Anti-Hypertensives Market, Japan, Treatment-Seeking Population (millions), 2002–2017 71
Figure 52: Anti-Hypertensives Market, Japan, Diagnosed Population (millions), 2002–2017 72
Figure 53: Anti-Hypertensives Market, Japan, Prescription Population (millions), 2002–2017 73
Figure 54: Anti-Hypertensives Market, Global, R&D Pipeline by Indication (%), 2011 74
Figure 55: Anti-Hypertensives Market, Global, R&D Pipeline by Phase (%), 2011 75
Figure 56: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market (%), 2011 76
Figure 57: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market (%), 2011 80
Figure 58: Anti-Hypertensives Market, Global, Market Share by Company (%), 2010 90
Figure 59: Anti-Hypertensives Market, Global, SWOT – Novartis, 2011 92
Figure 60: Anti-Hypertensives Market, Global, SWOT – Merck, 2011 93
Figure 61: Anti-Hypertensives Market, Global, SWOT – Daiichi Sankyo, 2011 94
Figure 62: Anti-Hypertensives Market, Global, SWOT – Sanofi, 2011 95
Figure 63: Anti-Hypertensives Market, Global, SWOT – AstraZeneca, 2011 96
Figure 64: Anti-Hypertensives Market, Global, SWOT – United Therapeutics, 2011 98
Figure 65: Anti-Hypertensives Market, Global, SWOT – Actelion Ltd, 2011 100
Figure 66: Anti-Hypertensives Market, Global, SWOT – Pfizer, 2011 101
Figure 67: Anti-Hypertensives Market, Global, Deals by Type (%), 2005–2011 102
Figure 68: Anti-Hypertensives Market, Global, M&A Deals by Year, 2005–2011 103
Figure 69: Anti-Hypertensives Market, Global, M&A Deals by Geography, 2005–2011 104
Figure 70: Anti-Hypertensives Market, Global, Major Licensing Agreements by Indication (%), 2005–2011 107
Figure 71: Anti-Hypertensives Market, Global, Major Licensing Agreements by Phase (%), 2005–2011 108
Figure 72: Anti-Hypertensives Market, Global, Major Licensing Agreements by Geography (%), 2005–2011 108
Figure 73: GBI Research Market Forecasting Model 117
Companies mentioned
Novartis
Merck
Daiichi Sankyo
Sanofi
AstraZeneca
United Therapeutics
Actelion
Pfizer
To order this report:
Therapy Industry: Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker